U.S. Markets close in 1 hr 9 mins

Moffitt licensing deal could provide new approach for some cancer patients

Margie Manning
American City Business Journals
Moffitt licensing deal could provide new approach for some cancer patients

Moffitt Cancer Center and MultiVir Inc., a Houston-based immune oncology company, have agreed to work together to develop a personalized cancer vaccine. The therapeutic vaccine, made up of a patient’s own cells, would activate cancer-fighting immune cells to target a genetic mutation found in nearly 50 percent of all cancers, Moffitt said in a press release. Moffitt, based in Tampa and the only Florida institution designated by the National Cancer Institute as a comprehensive cancer center, is a leader in the life sciences industry that economic developers hope to expand in the Tampa Bay area, because of the high-skill, high-wage jobs in the sector.